Table 4.
Reasons for not completing INH treatment for latent tuberculosis infection
| Reason |
Home follow-upa |
Clinic follow-upb |
P-valuec | ||
|---|---|---|---|---|---|
| N=986 | (%) | N=2932 | (%) | ||
| Adverse reaction |
24 |
(2.4) |
105 |
(3.6) |
0.24 |
| Abnormal liver enzymesd |
3 |
(0.3) |
40 |
(1.4) |
0.02 |
|
INH –related hepatitise |
1 |
(0.1) |
23 |
(0.8) |
0.06f |
| Rash |
7 |
(0.7) |
30 |
(1.0) |
0.58 |
| Other symptomsg |
14 |
(1.4) |
35 |
(1.2) |
0.58 |
| Refused/Losth | 75 | (7.6) | 680 | (23.2) | <0.001 |
aHome-based follow-up with community health workers and public health nurses.
bClinic-based follow-up.
cAnalysis by chi-square or Fisher’s exact test, adjusted for multiple comparisons.
dAny abnormality of liver enzymes associated with treatment discontinuation.
eSubset of patients with abnormal liver enzymes with isoniazid-related hepatitis, based on chart review.
fp-value for INH-related hepatitis only.
gAny other intolerable symptom that necessitated treatment discontinuation such as headache, dizziness, fatigue, among others.
hRefused to continue treatment or were lost to follow-up.